The authors said the estimated costs of Leqembi to Medicare are conservative and spending on the Alzheimer’s treatment may increase more than anticipated
The Alzheimer's Association, which lobbies on behalf of patients living with the disease, estimates Alzheimer's and other forms of dementia will cost the U.S. $345 billion this year. Those costs could rise to $1 trillion by 2050, according to the association.
"But it's not cost that should determine if people have access to life improving care — it's about the impact on people," Egge said."Treatments taken in the early stages of Alzheimer's could mean a better quality of life."
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 bln a year, study findsWide coverage of Alzheimer's drug Leqembi would raise future costs for the U.S. Medicare health plan by $2 billion to $5 billion a year, according to a study led by researchers at the University of California, Los Angeles (UCLA).
Lire la suite »
Cook County couple, Chicago social worker charged in $1.16M Medicare fraud schemeA husband-and-wife team, along with a Chicago social worker, have been indicted for allegedly scheming to defraud Medicare of over $1.16 million.
Lire la suite »
Pfizer CEO says Medicare will likely face legal action over drug price negotiationsPfizer CEO Albert Bourla argued the Biden administration's plan will cut profits and force Big Pharma companies to pull back on developing medicines.
Lire la suite »
Social Security, Medicare, federal salaries: What payments may be delayed in debt ceiling standoffThe U.S. may not have enough money to pay its bills as soon as June 1. At that point, it's unclear when and to whom the government would dole out funds.
Lire la suite »
US Drug Price Plan 'Negotiation With a Gun to Your Head'Pfizer Chief Executive Albert Bourla called US plans to negotiate drug prices for its Medicare health program 'negotiation with a gun to your head.' TwitteRx
Lire la suite »
Pfizer CEO calls US drug price plan 'negotiation with a gun to your head'Pfizer Inc Chief Executive Albert Bourla called U.S. plans to negotiate drug prices for its Medicare health program 'negotiation with a gun to your head' and said he expects drugmakers to sue in an attempt to halt the process.
Lire la suite »